

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Boill Healthcare Holdings Limited**

### **保集健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1246)**

### **PROFIT WARNING**

This announcement is made by Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2020 (the “**Period**”), the Group is expected to record a significant increase in the consolidated net loss for the Period of not less than 50%, as compared with the consolidated net loss for the six months ended 30 September 2019 (the “**Corresponding Period**”) of approximately HK\$49 million.

The Board considers that such substantial increase in unaudited consolidated net loss for the Period was mainly due to the following:

- (i) the revenue of sales of properties has dropped by approximately 75% for the Period as compared with the Corresponding Period resulting from (a) the outbreak of the coronavirus disease (COVID-19) (the “**Pandemic**”) since early 2020; and (b) the low level of completed properties held for sale by the Group;
- (ii) the construction works of the Phase 1 and Phase 2 of a resort project located at No. 1, Sheyuan Road, Sheshan Town, Songjiang District, Shanghai, the People’s Republic of China (the “**Project**”) were completed and the sales, leases and operation of the Project commenced in the second half of year 2019. Due to the adverse impact of the Pandemic, the revenue generated from the Project was approximately HK\$4 million

for the Period (2019: approximately HK\$0.4 million) while the cost incurred for daily operation was not less than HK\$22 million for the Period (2019: approximately HK\$7 million);

- (iii) the fair value gains of approximately HK\$0.7 million on the investment properties and investment properties under construction were derived for the Period (2019: approximately HK\$44 million); and
- (iv) the interest expenses on borrowings increased to approximately HK\$45 million for the Period (2019: approximately HK\$36 million) due to the increase of borrowings and the average interest rate.

The Company is still in the process of finalising the interim results of the Group for the Period. The information contained in this announcement is only based on preliminary assessment made by the Board with reference to the unaudited consolidated management accounts of the Group for the Period and other information currently available to the Board, which have not been audited or reviewed by the Company's auditors nor reviewed by the audit committee of the Company. The interim results of the Group for the Period may be subject to adjustments, if any, upon further review.

Shareholders and potential investors are advised to read carefully the interim results announcement of the Group for the Period for further details, which is expected to be published on or about 27 November 2020.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Boill Healthcare Holdings Limited**  
**Dai Dong Xing**  
*Executive Director and Chairman*

Hong Kong, 17 November 2020

*As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung, Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.*

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*